Device Review Program Faces Organizational Changes; User Fees Coming?
This article was originally published in The Silver Sheet
NOVEL DEVICE PREMARKET REVIEW OPTIONS will be a primary focus of the Center for Devices and Radiological Health’s new office dedicated to in vitro diagnostic products. The IVD office will embody the device center’s "total product life cycle" approach to regulating products, which seeks to eliminate the division between premarket and postmarket activities. A new division devoted to cardiovascular devices, new leadership and the possibility of user fees are among the changes facing the CDRH’s Office of Device Evaluation. Meanwhile, ODE looks for ways to improve its expedited and modular PMA options and to encourage greater use of abbreviated 510(k)s and third parties
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.